Ruiwen Zhang
- Molecular Biology top 1%
- Oncology top 0.5%
- Cancer Research top 1%
- Immunology top 5%
- Pulmonary and Respiratory Medicine top 5%
- Co-authors
- Hui WangSudhir AgrawalZhuo ZhangJiang‐Jiang QinRobert B. DiasioSubhasree NagElizabeth R. RayburnZhihong Lu
- Topics
- Cancer-related Molecular Pathways (55 papers)Cancer therapeutics and mechanisms (21 papers)Ubiquitin and proteasome pathways (15 papers)
- Journals
- CellProceedings of the National Academy of SciencesJournal of the American Chemical Society
- Partner nations
- United StatesChinaCzechia
In The Last Decade
Ruiwen Zhang
215 papers receiving 9.4k citations
Hit Papers
Peers
Comparison fields: 5 of 165
- Molecular Biology 6.0k
- Oncology 3.6k
- Cancer Research 1.3k
- Immunology 711
- Pulmonary and Respiratory Medicine 667
Countries citing papers authored by Ruiwen Zhang
This map shows the geographic impact of Ruiwen Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruiwen Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruiwen Zhang more than expected).
Fields of papers citing papers by Ruiwen Zhang
This network shows the impact of papers produced by Ruiwen Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruiwen Zhang. The network helps show where Ruiwen Zhang may publish in the future.
Co-authorship network of co-authors of Ruiwen Zhang
This figure shows the co-authorship network connecting the top 25 collaborators of Ruiwen Zhang. A scholar is included among the top collaborators of Ruiwen Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruiwen Zhang. Ruiwen Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Futurebreakdown → | 56 |
| 2 | 13 | |
| 3 | 0 | |
| 4 | 6 | |
| 5 | 1 | |
| 6 | 2 | |
| 7 | 6 | |
| 8 | 24 | |
| 9 | 1 | |
| 10 | 38 | |
| 11 | 1 | |
| 12 | 36 | |
| 13 | 25 | |
| 14 | 40 | |
| 15 | 53 | |
| 16 | Anticancer Activity and Molecular Mechanisms of Action of Makaluvamines and Analogues | 7 |
| 17 | 42 | |
| 18 | Preclinical pharmacological evaluations of SMA-491, a nucleoside analogue related to sangivamycin | 1 |
| 19 | Preclinical studies with dihydronaphthalene monophenol (NSC D725087), a vascular targeting agent, and its monophosphate prodrug (NSC D725088). | 2 |
| 20 | 108 |
About Ruiwen Zhang
Ruiwen Zhang is a scholar working on Toxicology, Oncology and Biotechnology, having authored 219 papers that have together received 9.7k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (55 papers), Cancer therapeutics and mechanisms (21 papers) and Ubiquitin and proteasome pathways (15 papers). The work is most often cited by research in Oncology (3.6k citations), Molecular Biology (6.0k citations) and Cancer Research (1.3k citations). Ruiwen Zhang has collaborated with scholars based in United States, China and Czechia. Frequent co-authors include Hui Wang, Sudhir Agrawal, Zhuo Zhang, Jiang‐Jiang Qin, Robert B. Diasio, Subhasree Nag, Elizabeth R. Rayburn, Zhihong Lu, Li Mao and Ming‐Hai Wang. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.